AI3SD Winter Seminar w/ Sia Togia

Natural Language Processing in AI-driven drug discovery; what it is, why it matters and how (not) to do it

Natural Language Processing (NLP) has been used in drug discovery for decades. However, the emergence of AI-driven drug discovery coupled with recent advances in NLP have redefined the relationship between the two fields. This talk will focus on major classes of NLP techniques used in drug discovery as well as challenges arising when creating real-world biomedical NLP systems. The talk will cover topics such as dataset selection and construction, evaluation, models, methodology, research process and structure of NLP systems in AI-driven drug discovery.

Register →

Sia Togia

Lead AI Scientist

I am a Lead AI Scientist at BenevolentAI with a focus on NLP. I have a PhD in NLP from the University of Cambridge and have spent the last six years building NLP systems in the AI industry, mostly in the biomedical domain. I specialise in Information Extraction, Information Retrieval and Knowledge Representation and have a strong interest in creating NLP systems that solve real-world problems.

More Posts

You Might Also Like

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
Notifications of persons discharging managerial responsabilities
May 5, 2022
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
PDMR Notification (Jean Raby)
May 5, 2022
Notifications of Major Holdings
Apr 29, 2022